Effects of the Addition of Bevacizumab or Iniparib to Standard Chemotherapy for Breast Cancer, Including Triple-Negative Disease, in the Neoadjuvant and Metastatic Settings


Effects of the Addition of Bevacizumab or Iniparib to Standard Chemotherapy for Breast Cancer, Including Triple-Negative Disease, in the Neoadjuvant and Metastatic Settings
Slides from ASCO 2011 presentations and comments from Drs Geyer, Burstein and Gralow

Brufsky A et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. Proc ASCO 2011;Abstract 1010.

Dr Gralow is Professor of Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center and Director of Breast Medical Oncology at Seattle Cancer Care Alliance/University of Washington in Seattle, Washington.